308 related articles for article (PubMed ID: 29543887)
21. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status.
Langdahl BL; Marin F; Shane E; Dobnig H; Zanchetta JR; Maricic M; Krohn K; See K; Warner MR
Osteoporos Int; 2009 Dec; 20(12):2095-104. PubMed ID: 19350340
[TBL] [Abstract][Full Text] [Related]
22. Effects of Denosumab and Alendronate on Bone Health and Vascular Function in Hemodialysis Patients: A Randomized, Controlled Trial.
Iseri K; Watanabe M; Yoshikawa H; Mitsui H; Endo T; Yamamoto Y; Iyoda M; Ryu K; Inaba T; Shibata T
J Bone Miner Res; 2019 Jun; 34(6):1014-1024. PubMed ID: 30690785
[TBL] [Abstract][Full Text] [Related]
23. The clinical utility of TRACP-5b to monitor anti-resorptive treatments of osteoporosis.
Gossiel F; Ugur A; Peel NFA; Walsh JS; Eastell R
Osteoporos Int; 2022 Jun; 33(6):1357-1363. PubMed ID: 35102444
[TBL] [Abstract][Full Text] [Related]
24. Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial.
Tamechika SY; Sasaki K; Hayami Y; Ohmura SI; Maeda S; Iwagaitsu S; Naniwa T
Arch Osteoporos; 2018 Jun; 13(1):67. PubMed ID: 29904824
[TBL] [Abstract][Full Text] [Related]
25. Significant improvement of bone mineral density by denosumab without bisphosphonate pre-treatment in glucocorticoid-induced osteoporosis.
Suzuki T; Nakamura Y; Kato H
Mod Rheumatol; 2018 Sep; 28(5):885-889. PubMed ID: 29251033
[TBL] [Abstract][Full Text] [Related]
26. Treatment of osteoporosis secondary to hypogonadism in prostate cancer patients: a prospective randomized multicenter international study with denosumab vs. alendronate.
Doria C; Mosele GR; Solla F; Maestretti G; Balsano M; Scarpa RM
Minerva Urol Nefrol; 2017 Jun; 69(3):271-277. PubMed ID: 27813398
[TBL] [Abstract][Full Text] [Related]
27. Additional beneficial effects of alendronate in growth hormone (GH)-deficient adults with osteoporosis receiving long-term recombinant human GH replacement therapy: a randomized controlled trial.
Biermasz NR; Hamdy NA; Janssen YJ; Roelfsema F
J Clin Endocrinol Metab; 2001 Jul; 86(7):3079-85. PubMed ID: 11443170
[TBL] [Abstract][Full Text] [Related]
28. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: a 12-month randomized, placebo-controlled clinical trial.
Stoch SA; Saag KG; Greenwald M; Sebba AI; Cohen S; Verbruggen N; Giezek H; West J; Schnitzer TJ
J Rheumatol; 2009 Aug; 36(8):1705-14. PubMed ID: 19487264
[TBL] [Abstract][Full Text] [Related]
29. Predictors of denosumab efficacy in treating osteoporosis in patients with rheumatoid arthritis: a Japanese multicenter study.
Hattori K; Hirano Y; Kanayama Y; Takahashi N; Ishiguro N; Kojima T
Nagoya J Med Sci; 2019 Nov; 81(4):571-585. PubMed ID: 31849375
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of denosumab on bisphosphonate-treated osteoporosis and osteopenia in systemic rheumatic disease patients receiving glucocorticoids.
Tamechika SY; Ohmura SI; Maeda S; Naniwa T
J Bone Miner Metab; 2023 Mar; 41(2):203-211. PubMed ID: 36512086
[TBL] [Abstract][Full Text] [Related]
31. Effect of alendronate on bone mineral density and bone turnover markers in post-gastrectomy osteoporotic patients.
Iwamoto J; Uzawa M; Sato Y; Takeda T; Matsumoto H
J Bone Miner Metab; 2010 Mar; 28(2):202-8. PubMed ID: 19690798
[TBL] [Abstract][Full Text] [Related]
32. Denosumab in postmenopausal women with low bone mineral density.
McClung MR; Lewiecki EM; Cohen SB; Bolognese MA; Woodson GC; Moffett AH; Peacock M; Miller PD; Lederman SN; Chesnut CH; Lain D; Kivitz AJ; Holloway DL; Zhang C; Peterson MC; Bekker PJ;
N Engl J Med; 2006 Feb; 354(8):821-31. PubMed ID: 16495394
[TBL] [Abstract][Full Text] [Related]
33. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
Klotz LH; McNeill IY; Kebabdjian M; Zhang L; Chin JL;
Eur Urol; 2013 May; 63(5):927-35. PubMed ID: 23040208
[TBL] [Abstract][Full Text] [Related]
34. Once-monthly oral ibandronate provides significant improvement in bone mineral density in postmenopausal women treated with glucocorticoids for inflammatory rheumatic diseases: a 12-month, randomized, double-blind, placebo-controlled trial.
Hakala M; Kröger H; Valleala H; Hienonen-Kempas T; Lehtonen-Veromaa M; Heikkinen J; Tuomiranta T; Hannonen P; Paimela L;
Scand J Rheumatol; 2012 Aug; 41(4):260-6. PubMed ID: 22803768
[TBL] [Abstract][Full Text] [Related]
35. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
36. The Efficacy of Minodronate in the Treatment of Glucocorticoid-induced Osteoporosis.
Hasegawa E; Ito S; Takai C; Kobayashi D; Nomura Y; Otani H; Abe A; Ishikawa H; Murasawa A; Narita I; Nakazono K
Intern Med; 2018 Aug; 57(15):2169-2178. PubMed ID: 29607978
[TBL] [Abstract][Full Text] [Related]
37. Bone Mineral Density After Transitioning From Denosumab to Alendronate.
Kendler D; Chines A; Clark P; Ebeling PR; McClung M; Rhee Y; Huang S; Stad RK
J Clin Endocrinol Metab; 2020 Mar; 105(3):e255-64. PubMed ID: 31665314
[TBL] [Abstract][Full Text] [Related]
38. Primary prevention of glucocorticoid-induced osteoporosis with intravenous pamidronate and calcium: a prospective controlled 1-year study comparing a single infusion, an infusion given once every 3 months, and calcium alone.
Boutsen Y; Jamart J; Esselinckx W; Devogelaer JP
J Bone Miner Res; 2001 Jan; 16(1):104-12. PubMed ID: 11149473
[TBL] [Abstract][Full Text] [Related]
39. Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate.
Sambrook PN; Roux C; Devogelaer JP; Saag K; Lau CS; Reginster JY; Bucci-Rechtweg C; Su G; Reid DM
Bone; 2012 Jan; 50(1):289-95. PubMed ID: 22061864
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial.
Brown JP; Prince RL; Deal C; Recker RR; Kiel DP; de Gregorio LH; Hadji P; Hofbauer LC; Alvaro-Gracia JM; Wang H; Austin M; Wagman RB; Newmark R; Libanati C; San Martin J; Bone HG
J Bone Miner Res; 2009 Jan; 24(1):153-61. PubMed ID: 18767928
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]